Arndt Schottelius

Dr. Arndt Schottelius joined the Company in April 2020 following a long career with positions at a number of esteemed biopharmaceutical companies. Before joining Affimed, Dr. Schottelius served Kymab Ltd, Cambridge, UK, as Executive Vice President & Head of Research & Development, where he was responsible for building a growing pipeline of 15 proprietary drug candidates, including antibody programs in oncology.